Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Barinthus Biotherapeutics's revenue per share for the
three
months ended in Mar. 2026 was €0.00.
Barinthus Biotherapeutics's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00.
During the past 12 months, the average Revenue Per Share Growth Rate of Barinthus Biotherapeutics was -100.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Barinthus Biotherapeutics's Revenue per Share or its related term are showing as below:
During the past 7 years, Barinthus Biotherapeutics's highest 3-Year average Revenue Per Share Growth Rate was 236.20% per year. The lowest was -94.10% per year. And the median was 71.05% per year.
STU:2AB's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.1 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
Barinthus Biotherapeutics (STU:2AB) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Barinthus Biotherapeutics Revenue per Share Related Terms
Barinthus Biotherapeutics Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Revenue per Share Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's PS Ratio falls into.
Barinthus Biotherapeutics Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Barinthus Biotherapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Revenue per Share of €0.00 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 769 companies in the Biotechnology industry.
Is Barinthus Biotherapeutics' Revenue per Share too high?
Barinthus Biotherapeutics' current Revenue per Share is €0.00. Based on the distribution chart, Barinthus Biotherapeutics ranks #999999 out of 769 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Revenue per Share compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #999999 out of 769 companies for Revenue per Share. This places Barinthus Biotherapeutics in the lower half of its industry. The industry median Revenue per Share is 3.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.10, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Revenue per Share of €0.00. The stock's GF Value™ is €0.97, compared to a current price of €0.53 — trading 45.9% below its estimated fair value. The current Revenue per Share is €0.00. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Revenue per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.53 is trading 45.9% below its estimated GF Value™ of €0.97.
Key valuation signals for STU:2AB:
Revenue per Share: €0.00
GF Value™: €0.97 vs. price of €0.53 (45.9% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
